News

Real-world use of Octave Bioscience’s artificial intelligence (AI)-powered blood test for classifying multiple sclerosis (MS) activity has increased substantially in the few years since its commercial U.S. launch. In clinical practice, the multiple sclerosis disease activity (MSDA) test has mainly been used for routine monitoring, with additional uses…

First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert Bermel, MD, of…

Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘ multiple sclerosis (MS) medication for relapsing forms of the disease, that could be injected at home. The new formulation is designed to be given under the skin, or subcutaneously, every…

In multiple sclerosis (MS), mindfulness may increase the time a patient spends asleep while in bed, but physical activity appears to have small and inconsistent benefits on sleep. That’s according to a meta-analysis of five published studies that looked at the impact of interventions designed to improve sleep among…

A new formulation — a film that dissolves under the tongue — of cladribine for treating multiple sclerosis (MS) has moved closer to clinical testing, according to an update from its developer. Bionxt Solutions announced that it has completed manufacturing of a clinical-grade batch of BNT23001, its…

Using disease-modifying treatments shortly prior to or during pregnancy does not seem to increase the risk of neurodevelopmental disorders in exposed children, according to a real-world study of mothers with multiple sclerosis (MS). Still, sphingosine-1-phosphate (S1P) receptor modulators, which include therapies such as Gilenya (fingolimod), Mayzent…

A blood test being developed by Roche to measure a marker of nerve cell damage has received CE mark approval for the detection of neuroinflammation in people with relapsing-remitting multiple sclerosis (RRMS). Called Elecsys Neurofilament Light Chain (NfL), the test is designed to measure NfL levels, which are…

People with diabetes are significantly more likely — with nearly 60% higher odds — to develop multiple sclerosis (MS) than those without the metabolic disease, which is marked by high blood sugar levels, according to a new systematic review and meta-analysis. A significant association was also observed specifically between…

The portable neuromodulation stimulator (PoNS), a noninvasive device that’s approved to improve walking and balance in people with multiple sclerosis (MS), has been acquired by Bioness Medical. The device was originally developed by Helius Medical Technologies, which rebranded to Solana in September of last year as…

Physical exercise may help reduce inflammation in multiple sclerosis (MS) by changing the activity of immune T-cells, a new study reports. Findings suggest this effect may depend in part on signaling through the vagus nerve, which connects the brain to other organs and helps regulate automatic bodily functions.

Urinary issues are a frequent and distressing reality for women with multiple sclerosis (MS), and new research suggests these symptoms may diminish quality of life, specifically by fueling feelings of loneliness. While the physical burden of bladder dysfunction is well-documented, this study highlights a critical emotional link, suggesting that…

The first participant has been dosed in a Phase 1 clinical trial testing TNV262, an experimental therapy that Tenvie Therapeutics is developing as a potential treatment for multiple sclerosis (MS) and other conditions including obesity and cardiovascular disease. The Phase 1a/1b study will test single and multiple doses…

While doctors and specialists view “high-quality” multiple sclerosis (MS) care through the lens of effective treatments and faster diagnosis, patients have a different priority: being heard, according to a recent study. Researchers interviewed a range of specialists and patients to bridge the gap in how these groups define excellence…

A history of infectious mononucleosis, often called “mono,” more than triples the risk of developing multiple sclerosis (MS), according to a new study. While scientists have long suspected a link between the Epstein-Barr virus (EBV) and MS, these findings provide evidence that a documented case of mono serves…

Exposure to higher levels of ground-level ozone may significantly increase the risk that children and teens will develop multiple sclerosis (MS), a new Italian study suggests. Researchers found that for every unit increase in ozone levels in the three years preceding the first MS symptoms, the likelihood of…

A pair of studies showed that a group of nerve cells essential for cognition may be particularly vulnerable to damage in multiple sclerosis (MS). Researchers found that CUX2 neurons — specialized cells in the brain’s cortex, which governs complex thinking — are…

A 12-week intervention combining breathing exercises, cold exposure, and meditation — known as the Wim Hof Method (WHM) — or a lifestyle intervention aimed at improving physical activity and dietary habits may help reduce inflammation linked to disease progression in people with multiple sclerosis (MS), a pilot study suggests.

In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That is the key finding of a new study by researchers in the Netherlands, who zeroed in on the protein as a driver of MS.

The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…

A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to…

Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…

MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money…

The cells that line the inside of the gut — known as intestinal epithelial cells — may play a key role in triggering inflammation that drives multiple sclerosis (MS), a study showed. The study found that these cells can activate a type of T-cell known as Th17 cells. These…

More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often including vitamin supplements and drugs used to manage symptoms such as muscle stiffness, pain, and mental health issues — to treat their MS. That’s according to a real-world study in…

A new study being funded by the National Multiple Sclerosis Society (NMSS) will seek to better understand how women with multiple sclerosis (MS) navigate menopause and develop resources to address gaps in care. The study, “The Menopausal Transition, MS Symptom Management, and Multidisciplinary Care Gaps,” will use input from…

Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive…

Multiple sclerosis (MS) has become far more common in England over the past two decades, but people diagnosed more recently are living longer, according to a study led by University College London (UCL). The shift reflects major advances in MS diagnosis and care. But researchers found that social…

Variations in the activity of a protein called p21 may underlie the differences in the activity of myelin-repairing cells in the brains of people with multiple sclerosis (MS), according to a new study. The findings may help to explain why different people with MS develop different forms of…

Exercises to strengthen the respiratory muscles — the muscles in the chest needed to move air in and out of the lungs when breathing — can help improve lung function in people with multiple sclerosis (MS), according to a new analysis. This type of exercise, known as respiratory muscle…

IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested…